Objective:The aim of our study was to observe the efficiency and toxicity of oxaliplatin (L-OHP) combined with CF/5-FU in patients with advanced primary hepatocellular carcinoma.Methods:Twenty patients with advanced p...Objective:The aim of our study was to observe the efficiency and toxicity of oxaliplatin (L-OHP) combined with CF/5-FU in patients with advanced primary hepatocellular carcinoma.Methods:Twenty patients with advanced primary hepatocellular carcinoma had recurrence/metastasis after multiple courses of TACE (cisplatin and epirubicin,etc.).All patients were treated with FOLFOX4 regimen of the combination of oxaliplatin and leucovorin and 5-fluorouracil.Treatment was repeated every 2 weeks until disease progression or unacceptable adverse effects occurred.The efficiency was evaluated according to RECIST criteria,and toxicities according to American National Cancer Institute Common Toxicity Criteria (NCI CTC),respectively.Results:Twenty patients were assessable for the objective efficiency and for toxicity.No patient achieved complete response (CR),4 patients were partial response (PR),8 patients were stable disease (SD),8 patients were disease progression (PD);Time to tumor progression (TTP) of the patients ranged from 1.5 to 4.8 months,median TTP was 2.2 months;Overall survival (OS) of the patients ranged from 3 to 10.2 months,median OS was 5 months.The 2 patients' serum AFP level decreasing.Sixteen patients relieved the symptoms obviously,stabilized or raised up Karnofsky Score.The toxicities were mainly grade I-II arrest of bone marrow (50%),mild neurotoxicity (30%) and mild reaction of gastrointestinal tract (40%).Conclusion:FOLFOX4 regimen is effective and safe for patients with advanced primary hepatocellular carcinoma.It can be worthy of further clinical investigation.展开更多
Objective:The aim of the study was to observe the therapeutic effect of FOLFOX4 regimen plus Fufangchangtai decoction on postoperative colorectal cancers.Methods:Thirty postoperative colorectal cancer patients were al...Objective:The aim of the study was to observe the therapeutic effect of FOLFOX4 regimen plus Fufangchangtai decoction on postoperative colorectal cancers.Methods:Thirty postoperative colorectal cancer patients were allocated into control and experiment groups respectively.Patients in experiment group were given Fufangchangtai decoction combined with FOLFOX4 regimen.Patients in control group were given FOLFOX4 regimen alone.Efficacy was evaluated after 2 periods of treatment.Results:The improvement rate of symptoms were 86.6% in experiment group compared to 53.3% in control group.KPS was stable in experiment group,and decreased in control group.QOL was increased in experiment group,and stable in control group after the treatment.For impact of immunity parameters,there were enhancements of CD3+ and CD4+ in experiment group,while they did not change in control group.In experiment group,WBC reduction was slighter than that of control group.The differences were not remarkable in PLT reduction,alimentary response,and toxicity of liver and kidney and nervous system.Conclusion:The clinical observation showed that Fufangchangtai decoction plus FOLFOX4 regimen could effectively enhance KPS,improve the symptoms,the quality of life and the immunity state,and down-regulate the side effects.In conclusion,Fufangchangtai decoction can decrease the toxicity so as to increase the treatment effect.展开更多
Objective：To evaluate the efficacy and safety of Yiqi Zhuyu Decoction（益气逐瘀汤,YZD） combined with oxaliplatin plus 5-flurouracil/leucovorin（FOLFOX-4） in the patients with metastatic colorectal cancer（MCRC）.Me...Objective：To evaluate the efficacy and safety of Yiqi Zhuyu Decoction（益气逐瘀汤,YZD） combined with oxaliplatin plus 5-flurouracil/leucovorin（FOLFOX-4） in the patients with metastatic colorectal cancer（MCRC）.Methods：A total of 120 patients with MCRC were randomly divided into the experimental group（FOLFOX-4 plus YZD,60 cases） and the control group（FOLFOX-4 plus placebo,60 cases）,according to the sequence of hospitalization from January 2005 to December 2007.The treatment was supposed to be continued until disease progression（PD） or for 48 weeks（i.e.,up to 24 cycles of FOLFOX-4）.Response rate （RR）,progression-free survival（PFS）,overall survival（OS） and adverse events（AEs） were observed.Results： RR was 41.5%in the experimental group and 34.0%in the control group[odds ratio（OR）：1.18,95%CI：0.77 to 1.82,P=0.432].Median PFS were 9.0 months and 8.0 months,respectively[hazard ratio（HR）：0.78,95% CI：0.53 to 1.15,P=0.215].Median OS were 21.0 months and 18.0 months（HR：0.65,95%CI：0.43 to 0.99, P=0.043） and grade 3/4 AEs were 56.6%and 76.7%（OR：0.61,95%CI：0.18 to 0.87,P=0.020）,respectively. Conclusions：YZD combined with FOLFOX-4 chemotherapy significantly improved OS in this first-line trial in the patients with MCRC and significantly decreased grade 3/4 AEs.However,RR was not improved,and PFS did not reach statistical significance by the addition of YZD.The treatment of YZD combined with FOLFOX-4 may be necessary in order to optimize efficacy and safety.展开更多
文摘Objective:The aim of our study was to observe the efficiency and toxicity of oxaliplatin (L-OHP) combined with CF/5-FU in patients with advanced primary hepatocellular carcinoma.Methods:Twenty patients with advanced primary hepatocellular carcinoma had recurrence/metastasis after multiple courses of TACE (cisplatin and epirubicin,etc.).All patients were treated with FOLFOX4 regimen of the combination of oxaliplatin and leucovorin and 5-fluorouracil.Treatment was repeated every 2 weeks until disease progression or unacceptable adverse effects occurred.The efficiency was evaluated according to RECIST criteria,and toxicities according to American National Cancer Institute Common Toxicity Criteria (NCI CTC),respectively.Results:Twenty patients were assessable for the objective efficiency and for toxicity.No patient achieved complete response (CR),4 patients were partial response (PR),8 patients were stable disease (SD),8 patients were disease progression (PD);Time to tumor progression (TTP) of the patients ranged from 1.5 to 4.8 months,median TTP was 2.2 months;Overall survival (OS) of the patients ranged from 3 to 10.2 months,median OS was 5 months.The 2 patients' serum AFP level decreasing.Sixteen patients relieved the symptoms obviously,stabilized or raised up Karnofsky Score.The toxicities were mainly grade I-II arrest of bone marrow (50%),mild neurotoxicity (30%) and mild reaction of gastrointestinal tract (40%).Conclusion:FOLFOX4 regimen is effective and safe for patients with advanced primary hepatocellular carcinoma.It can be worthy of further clinical investigation.
基金Supported by a grant from the Natural Science Foundation of Jiangsu Province, China (No. BK2006156)
文摘Objective:The aim of the study was to observe the therapeutic effect of FOLFOX4 regimen plus Fufangchangtai decoction on postoperative colorectal cancers.Methods:Thirty postoperative colorectal cancer patients were allocated into control and experiment groups respectively.Patients in experiment group were given Fufangchangtai decoction combined with FOLFOX4 regimen.Patients in control group were given FOLFOX4 regimen alone.Efficacy was evaluated after 2 periods of treatment.Results:The improvement rate of symptoms were 86.6% in experiment group compared to 53.3% in control group.KPS was stable in experiment group,and decreased in control group.QOL was increased in experiment group,and stable in control group after the treatment.For impact of immunity parameters,there were enhancements of CD3+ and CD4+ in experiment group,while they did not change in control group.In experiment group,WBC reduction was slighter than that of control group.The differences were not remarkable in PLT reduction,alimentary response,and toxicity of liver and kidney and nervous system.Conclusion:The clinical observation showed that Fufangchangtai decoction plus FOLFOX4 regimen could effectively enhance KPS,improve the symptoms,the quality of life and the immunity state,and down-regulate the side effects.In conclusion,Fufangchangtai decoction can decrease the toxicity so as to increase the treatment effect.
文摘Objective：To evaluate the efficacy and safety of Yiqi Zhuyu Decoction（益气逐瘀汤,YZD） combined with oxaliplatin plus 5-flurouracil/leucovorin（FOLFOX-4） in the patients with metastatic colorectal cancer（MCRC）.Methods：A total of 120 patients with MCRC were randomly divided into the experimental group（FOLFOX-4 plus YZD,60 cases） and the control group（FOLFOX-4 plus placebo,60 cases）,according to the sequence of hospitalization from January 2005 to December 2007.The treatment was supposed to be continued until disease progression（PD） or for 48 weeks（i.e.,up to 24 cycles of FOLFOX-4）.Response rate （RR）,progression-free survival（PFS）,overall survival（OS） and adverse events（AEs） were observed.Results： RR was 41.5%in the experimental group and 34.0%in the control group[odds ratio（OR）：1.18,95%CI：0.77 to 1.82,P=0.432].Median PFS were 9.0 months and 8.0 months,respectively[hazard ratio（HR）：0.78,95% CI：0.53 to 1.15,P=0.215].Median OS were 21.0 months and 18.0 months（HR：0.65,95%CI：0.43 to 0.99, P=0.043） and grade 3/4 AEs were 56.6%and 76.7%（OR：0.61,95%CI：0.18 to 0.87,P=0.020）,respectively. Conclusions：YZD combined with FOLFOX-4 chemotherapy significantly improved OS in this first-line trial in the patients with MCRC and significantly decreased grade 3/4 AEs.However,RR was not improved,and PFS did not reach statistical significance by the addition of YZD.The treatment of YZD combined with FOLFOX-4 may be necessary in order to optimize efficacy and safety.
